Samsung Biologics Stock Gains Momentum – Higher Upside Outlook Samsung Biologics has strong fundamentals with 25.8% YoY revenue and 35% YoY operating profit, elite margins, and a Strong Buy consensus, but the stock is discounted due to manufacturing continuity and labor legal risks. 2026년 08월 12일 English
Samsung Biologics Earnings Jump 25.8% YoY: Key Risks Samsung Biologics is rated Buy with strong growth and margins, but stock risk is driven by labor and legal disputes that could disrupt production, raise costs, and hurt future earnings. 2026년 06월 11일 English
